Charles Pryzant
Child & Adolescent Psychiatry · Dallas, TXNPI 1780881508
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,166 of the $8,685 with a category attached, or 82.5%. 25 manufacturers reported payments, led by Corium, LLC at 26.1% of the total. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$2K
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$870
- Otsuka America Pharmaceutical, Inc.$660
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$492
- Tris Pharma Inc$454
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,47017%
- Food & beverage$7,16683%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 50 | $2,268 |
| AbbVie(2 entities) | 66 | $1,091 |
| Supernus Pharmaceuticals, Inc. | 32 | $870 |
| Otsuka America Pharmaceutical, Inc. | 33 | $660 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $492 |
| Tris Pharma Inc | 30 | $454 |
| Alkermes, Inc. | 19 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $391 |
| Ironshore Pharmaceuticals Inc. | 23 | $380 |
| Johnson & Johnson | 16 | $341 |
| Lundbeck LLC | 8 | $197 |
| Neos Therapeutics, LP | 9 | $180 |
| Sunovion Pharmaceuticals Inc. | 9 | $160 |
| Noven Therapeutics, LLC | 6 | $101 |
| Neurocrine Biosciences, Inc. | 4 | $94 |
| Vertical Pharmaceuticals, LLC | 5 | $87 |
| Adlon Therapeutics L.p. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Shire North American Group Inc | 3 | $65 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Eisai Inc. | 3 | $47 |
| Neuronetics, Inc. | 2 | $28 |
| Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,685 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Adderall XrDextroamphetamine/Amphetamine | 11 | $4,258 |
| Fluoxetine Hcl | 20 | $144 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Dallas
- Janet CollinsDallas$5K
- Graham EmslieDallas$3K
- Andrew PortteusDallas$2K
- Callie EmeryDallas$2K
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.